Cargando…

A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia

Tumor microenvironment (TME) has been revealed as an important determinant of diagnosis and treatment response in AML patients. The scores of immune and stromal cell scores of AML in the intermediate-risk group from The Cancer Genome Atlas (TCGA) database were calculated using the Estimation of STro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Cong, Hu, Dong, Zheng, Jin'e, Cao, Shiyi, Zhu, Jiang, Chen, Xiangjun, Huang, Shiang, Yao, Junxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076319/ https://www.ncbi.nlm.nih.gov/pubmed/35528167 http://dx.doi.org/10.1155/2022/4010786

Ejemplares similares

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis
por: Lu, Cong, et al.
Publicado: (2020)

High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia
por: Du, Wen, et al.
Publicado: (2019)

Prognostic significance of CXCR4 expression in acute myeloid leukemia
por: Du, Wen, et al.
Publicado: (2019)

A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes
por: Zhao, Xiaoyan, et al.
Publicado: (2018)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia
por: Pallarès, Victor, et al.
Publicado: (2018)

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing
por: Wang, Bianhong, et al.
Publicado: (2016)

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication
por: Shahrin, Nur Hezrin, et al.
Publicado: (2022)

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
por: Pallarès, Victor, et al.
Publicado: (2017)

A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges
por: Awada, Hassan, et al.
Publicado: (2022)

Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores
por: Aijaz, Javeria, et al.
Publicado: (2020)

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2019)

Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia
por: Wang, Bian-Hong, et al.
Publicado: (2015)

Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients
por: Zeng, Mingyue, et al.
Publicado: (2019)

A novel scoring system for the quantitative prediction of prognosis in acute myeloid leukemia
por: Yu, Yang, et al.
Publicado: (2023)

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis
por: Mosrati, Mohamed Ali, et al.
Publicado: (2015)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
por: Blanco Sánchez, Alberto, et al.
Publicado: (2023)

A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia
por: Hu, Xiaoxia, et al.
Publicado: (2021)

A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia
por: Jiang, Feng, et al.
Publicado: (2021)

Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia
por: Zhang, Nan, et al.
Publicado: (2022)

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
por: Fan, Yi, et al.
Publicado: (2021)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
por: Iezza, Miriam, et al.
Publicado: (2023)

Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia()
por: Rong, Dade, et al.
Publicado: (2022)

Prognosis and Therapy When Acute Promyelocytic Leukemia and Other “Good Risk” Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm
por: Larson, Richard A., et al.
Publicado: (2011)

Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia
por: Chu, Yajing, et al.
Publicado: (2019)

Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
por: Hu, Xuanhan, et al.
Publicado: (2022)

Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
por: Yu, Sijian, et al.
Publicado: (2021)

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
por: Bou Samra, Elias, et al.
Publicado: (2012)

Immune-related gene risk score predicting the effect of immunotherapy and prognosis in bladder cancer patients
por: Zou, Yuantao, et al.
Publicado: (2022)

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies
por: Li, Dandan, et al.
Publicado: (2015)

A 6-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia
por: Elsayed, Abdelrahman H., et al.
Publicado: (2019)

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1
por: Han, Lijie, et al.
Publicado: (2022)

The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics
por: How, J, et al.
Publicado: (2013)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
por: Cressman, Sonya, et al.
Publicado: (2016)

Karyotype complexity and prognosis in acute myeloid leukemia
por: Stölzel, F, et al.
Publicado: (2016)

Cytogenetics’ impact on the prognosis of acute myeloid leukemia
por: Gupta, Monika, et al.
Publicado: (2019)

Clonal hematopoiesis and risk of acute myeloid leukemia
por: Young, Andrew L., et al.
Publicado: (2019)

Characteristics of Pyroptosis-Related Subtypes and Novel Scoring Tool for the Prognosis and Chemotherapy Response in Acute Myeloid Leukemia
por: Pan, Jingjing, et al.
Publicado: (2022)

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Medeiros, B C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_08u01365fjqd6ho5chmsk3rejo